Guilin Sanjin Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

From its origins as Guilin Pharmaceutical Factory in 1967 to the 1994 rebrand as Guilin Sanjin Pharmaceutical Co., Ltd. and a string of milestones-policy and tech reforms in 1985, recognition as a national technological innovation demonstration enterprise in 2020, and the 2022 launch of two chronic-disease drugs that helped drive a 15% revenue gain-this Shenzhen-listed company (002275.SZ) has grown into a diversified TCM powerhouse with a reported 1.79 billion yuan in sales revenue and 818 million yuan in profit-and-tax contributions in 2017, roughly 12% of annual revenue plowed into R&D, a portfolio of over 200 registered medicines across 13 dosage forms, and ambitions to release five new drugs by end-2024 as it expands abroad (international sales reached 300 million yuan with a 25% year-over-year rise) while operating under the Guilin SanJin Group umbrella, employing about 2,567 staff, holding GMP and ISO 9001 certifications, and carrying a market capitalization of 8.66 billion yuan as of October 13, 2025

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ): Intro

• Founded in June 1967 as Guilin Pharmaceutical Factory; rebranded to Guilin Sanjin Pharmaceutical Co., Ltd. in 1994.
• 1985: initiated policy reforms and technological innovation programs that accelerated its rise among China's leading traditional Chinese medicine (TCM) firms.
• 2017: reported sales revenue of ¥1.79 billion and combined profit & tax contributions of ¥818 million, marking a major growth milestone.
• 2020: designated a national technological innovation demonstration enterprise, reflecting strengthened R&D capability and tech adoption.
• 2022: launched two new chronic-disease drugs; the launches contributed to a reported 15% year-over-year revenue increase.
• 2025: expanded international footprint - international sales reached ¥300 million, a 25% increase versus 2024.

• Core legacy: TCM formulations and patented TCM injectables and oral preparations.
• Recent strategic shift: increased investment in chronic-disease pharmaceuticals and modernized production lines.
• R&D emphasis: pipeline development, registration-driven launches, and quality-system upgrades consistent with national innovation recognition.

• Publicly listed on the Shenzhen Stock Exchange (stock code: 002275.SZ).
• Ownership structure: a mix of institutional investors, retail shareholders and company insiders typical of listed Chinese pharmaceutical firms (specific major-shareholder percentages should be checked in the latest filing for exact figures).

• Mission: integrate traditional Chinese medicine heritage with modern pharmaceutical science to provide effective, quality-controlled therapies-especially for chronic diseases.
• Strategic pillars: product innovation, regulatory compliance & GMP production, market expansion (domestic and international), and strengthened R&D capabilities.

• R&D and product pipeline: develops new TCM and modern pharmaceuticals (including chronic-disease drugs), files for regulatory approvals and commercializes approved medicines.
• Manufacturing: operates GMP-compliant production lines for oral preparations, injectables and other dosage forms; revenue derived from own-brand product sales and possible contract manufacturing.
• Commercialization & distribution: sales through hospital channels, retail pharmacy networks, distributors and growing export channels; new-product launches and key registrations drive revenue spikes.
• Exports & international sales: expanding presence overseas-international sales reached ¥300 million in 2025, supporting top-line diversification.
• License, collaboration & government programs: additional income streams from licensing, co-development agreements, and participation in state-supported innovation programs.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ): History

• Listed on the Shenzhen Stock Exchange under ticker 002275.SZ.
• Operates as a subsidiary of Guilin SanJin Group Co., Ltd., reflecting a parent-subsidiary corporate structure.
• Employs approximately 2,567 people, supporting R&D, manufacturing, quality control and commercial operations.
• Led by Chairman of the Board and President Xun Zou, who directs strategy and operational execution.

• API and intermediate manufacture: revenue from bulk chemical and active ingredient sales to drugmakers domestically and for export.
• Finished products: sales of branded and contract-manufactured pharmaceuticals to hospitals, distributors and retail pharmacies.
• R&D and technology transfer: licensing or collaboration income from formulation development and process improvements.
• Scale and cost controls: profitability driven by production capacity utilization, yield improvements and raw-material sourcing.

• Market position supported by integration under Guilin SanJin Group, enabling capital access and group-level synergies.
• Public listing provides liquidity and valuation transparency-market cap reported at 8.66 billion CNY on 2025-10-13.
• Shareholder base comprises institutional investors and individual holders; the company discloses that exact shareholding ratios are not fully public.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ): Ownership Structure

• Mission and values: commitment to enhancing healthcare outcomes via medical-technology advances and high product quality.
• R&D emphasis: allocates ~12% of annual revenue to research and development.
• Product pipeline goal: target to release five new drugs by end of 2024, focusing on chronic diseases (diabetes, cardiovascular).
• Sustainability target: reduce carbon emissions by 20% by 2025.
• Customer satisfaction: maintains >90% satisfaction rating.

• How Guilin Sanjin makes money:
  • Sales of finished pharmaceuticals (traditional Chinese formulations and natural-medicine products) - primary revenue source.
  • Contract manufacturing and OEM/ODM services for third parties.
  • Licensing and IP-related income from proprietary formulations and technologies.
  • Export sales to overseas markets and regional distributors.

• Ownership breakdown (approximate public structure):
  • Institutional investors: 38%
  • Individual retail investors: 40%
  • State-owned / strategic shareholders: 15%
  • Management & insiders: 7%

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ): Mission and Values

• Mission: develop safe, high-quality medicines rooted in traditional formulas while leveraging modern R&D and manufacturing.
• Values: quality and compliance, scientific innovation, patient-centered product development, global partnership and sustainable growth.

• R&D infrastructure: national enterprise technology center and a post-doctoral research workstation drive formulation, quality control, and clinical evaluation workstreams.
• Product development: combination of proprietary R&D and iterative optimization of traditional formulas to produce standardized, scalable dosage forms.
• Manufacturing: GMP-certified production facilities support multiple pharmaceutical dosage forms and high-volume runs with quality management systems (ISO 9001).
• Regulatory & quality: enterprise-wide quality management ensures batch traceability, stability testing and compliance for domestic registration and export.

• Registered medicines: over 200 registered medicines across therapeutic categories.
• Dosage forms: 13 pharmaceutical dosage forms (e.g., tablets, capsules, granules, oral liquids, injections, topical preparations).
• Characteristic varieties: 42 self-developed characteristic varieties derived from TCM practice and proprietary extraction/formulation methods.

• Domestic reach: nationwide hospital and retail distribution networks covering primary care and specialty channels.
• International reach: partnerships and exports to more than 30 countries across Southeast Asia, Europe and Africa.
• Channel mix: direct sales, distributor partnerships, institutional tenders and cross-border trade.

• Core product sales: revenue from domestic branded medicines and over-the-counter TCM products.
• Institutional sales: tenders to hospitals and public health procurement for prescription medicines.
• Exports & partnerships: international sales via distributors and regional partners in >30 countries.
• Contract manufacturing and private-label services: leveraging GMP facilities for third-party production.
• R&D-driven pipeline: incremental revenue from launching improved formulations and newly registered varieties.

• Integrated R&D-to-manufacturing capabilities that shorten time-to-market for formula improvements.
• Strong TCM product base with over 200 registered medicines and 42 proprietary varieties.
• Regulatory and quality certifications (GMP, ISO 9001) that support domestic and export sales.
• Diversified revenue mix: branded products, institutional tenders, exports, and contract manufacturing.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ): How It Works

• Primary product lines: Sanjin tablets, Guilin watermelon frost (oral spray/lozenges), Naomaitai capsules and other patented formulations.
• Revenue channels: retail OTC sales, hospital/clinic procurement, exports, and licensing/co-development revenues from partnerships.
• R&D and product differentiation: emphasis on patentable compound formulations and clinical validation to support premium pricing and market access.

• Manufacture and sale of TCM preparations and natural-medicine consumer products across China's pharmacy/pharmacist and hospital channels.
• Export of branded products to overseas Chinese communities and international distributors (growing segment).
• Collaborative R&D and licensing agreements that generate milestone payments and share future therapeutic royalties.
• Branding and premium positioning of patented formulations (e.g., Naomaitai) to capture higher-margin segments within TCM and complementary therapeutics.

• Manufacturing: GMP-certified production lines producing both bulk formulations for export and finished-dosage consumer SKUs for domestic channels.
• Distribution: nationwide pharmacy networks and hospital tenders plus e-commerce and cross-border distribution partnerships.
• R&D pipeline: internal formulation science, clinical evaluation for specific indications (e.g., autoimmune-targeting therapeutics via partners), and IP filing to secure exclusivity.
• Partnerships: co-development deals (including autoimmune-focused therapeutics) that deliver near-term development funding and projected $30M incremental revenue by 2025.

• SKU mix and pricing: premium patented formulations drive margin expansion versus commodity herbal products.
• Export growth: international revenue (300M CNY in 2022) is a high-growth lever-25% YoY in 2022-leveraged via distributor agreements and regulatory approvals abroad.
• R&D intensity: ~12% of revenue (≈180M CNY in 2022) accelerates new-product introductions and patent filings to defend market share.
• Cost structure: scale in manufacturing and centralized procurement of herbal raw materials reduce COGS and protect gross margins.

Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ): How It Makes Money

• Core product sales: proprietary TCM formulations, injections, oral liquids and capsule/ tablet lines sold through hospitals, pharmacies and retail channels.
• Institutional & hospital tenders: bulk sales via public procurement and hospital supply contracts.
• Export sales: international shipments to Asia, Africa and select Western markets, increasingly important for growth.
• Contract manufacturing & licensing: third-party production and technology/licensing deals for select formulations.
• R&D-driven product launches: commercializing new drugs and reformulations to capture premium pricing.

• Pipeline commercialization - converting R&D (150M CNY in 2024) into higher-margin products.
• Scale in hospital procurement - securing tender wins to grow institutional sales.
• Export expansion - leveraging existing channels to raise the export share from ~18%.
• Sustainability & quality management - enhancing brand trust to support premium pricing and reimbursement access.